FDA Approvals, Diversified Product Pipeline, Produce Sales Growth, and Positive Study Outcomes - Research Report on Boston

    FDA Approvals, Diversified Product Pipeline, Produce Sales Growth, and
 Positive Study Outcomes - Research Report on Boston Scientific, Zimmer, St.
                          Jude, ResMed, and GenMark

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 21, 2013

NEW YORK, June 21, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Boston
Scientific Corporation (NYSE: BSX), Zimmer Holdings, Inc. (NYSE: ZMH), St.
Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), and GenMark
Diagnostics, Inc. (NASDAQ: GNMK). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Boston Scientific CorporationResearch Report

On June 18, 2013, Boston Scientific Corporation's (Boston Scientific) Vercise
Deep Brain Stimulation (DBS) System demonstrated significant improvement in
motor function for patients with Parkinson's disease. This is according to
interim data from the VANTAGE DBS study. Data from the six month follow-up of
up to 40 participants enrolled in the VANTAGE trial were presented at the
annual International Congress of Parkinson's Disease and Movement Disorders,
held at Sydney. Preliminary analysis of the VANTAGE study displays
approximately 60% mean improvement in motor function at six months post
implant, as assessed by UPDRS III when compared to baseline. "The VANTAGE
study is a key facet of our DBS program and emphasizes our commitment to
advancing therapy through clinical research with the Vercise DBS System," said
Maulik Nanavaty, President of the Boston Scientific Neuromodulation Division.
"The significance of the reduction in motor scores is a testament to the
capabilities of the Vercise System. We continuously strive to develop
innovative technologies that improve patient outcomes." The Full Research
Report on Boston Scientific Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/5649_BSX]

--

Zimmer Holdings, Inc.Research Report

On June 4, 2013, Zimmer Holdings, Inc. (Zimmer) announced that it has
completed the acquisition of Germany-based NORMED Medizin-Technik GmbH. The
acquired entity is a provider of technologies for the foot and ankle, hand and
wrist reconstruction and trauma markets. NORMED also develops a broad range of
specialized plates, screws and instruments. The Company stated that the
acquisition of NORMED will strengthen Zimmer's Extremities and Trauma product
portfolios and new product development capabilities in the fast growing foot
and ankle as well as hand and wrist segments. The Full Research Report on
Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/9cbd_ZMH]

--

St. Jude Medical Inc.Research Report

On June 11, 2013, St. Jude Medical, Inc. (St. Jude) announced that the US Food
and Drug Administration (FDA) has approved its next-generation Ellipse and SJM
Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac
resynchronization therapy defibrillators (CRT-Ds). These new devices are
designed with advanced technologies to provide preventative and adaptive
capabilities to address potential failures by lowering the risk of lead
abrasion, and to help overcome the inability to deliver high-voltage therapy
when needed. "St. Jude Medical strives to deliver the highest levels of
patient safety. The new Ellipse ICD and SJM Assura family of devices support
those efforts by providing added features that ensure effective therapy
delivery," said Eric S. Fain, M.D., President of the St. Jude Medical
Implantable Electronic Systems Division. "We are pleased that the FDA approved
these devices, allowing us to bring important safety and system reliability
enhancements to patients." The Full Research Report on St. Jude Medical Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/bf35_STJ]

--

ResMed Inc.Research Report

On June 5, 2013, ResMed Inc. (ResMed) reported that it has filed a lawsuit in
U.S. Federal Court, Southern District of California to stop infringement of
ResMed patents. The Company filed the action against the Chinese medical
device manufacturer, BMC Medical Co., Ltd. and its U.S. sales subsidiary, 3B
Products, LLC asserting patent infringement by its RESmart CPAP, RESmart Auto
CPAP devices; and the Willows nasal pillows patient interface and the iVolve
nasal mask. "ResMed has built its unique market differentiation by investing
in superior technology and medical science-driven innovation for
sleep-disordered breathing therapy," said David Pendarvis, ResMed Global
General Counsel and Chief Administrative Officer. "We will continue to defend
our proprietary technology by enforcing our patents." The Full Research Report
on ResMed Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/ba41_RMD]

--

GenMark Diagnostics, Inc.Research Report

On June 17, 2013, GenMark Diagnostics, Inc. (GenMark) updated its annual
revenue guidance for FY 2013 (period ending December 31, 2013). The Company
stated that the guidance update resulted from the additional uncertainties
relating to the future revenue contribution from its largest customer,
together with persisting reimbursement and other challenges affecting the
emerging pharmacogenomics market sector,. The Company now anticipates annual
revenue of approximately $30 million, down compared to its original estimate
of approximately $35 million. Hany Massarany, GenMark's President and Chief
Executive Officer, said, "As previously communicated, we remained prudently
cautious regarding the future revenue contribution from the pharmacogenomics
sector, including our single largest customer. In light of the recent
developments which introduced additional uncertainty regarding this customer,
we have taken a more conservative outlook and reduced our revenue expectations
for the remainder of the year." The Full Research Report on GenMark
Diagnostics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/ab23_GNMK]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.